Filing Flows › TriSalus Life Sciences (TLSI) › Q4 2024
TriSalus Life Sciences (TLSI) Q4 2024 earnings results (fourth quarter 2024)
10-K filed Apr 15, 2025
TriSalus Life Sciences (TLSI) reported revenue of $8.3M for the fourth quarter 2024 (Q4 2024), +44% from a year earlier and +12% from the quarter before. Operating margin was -91.8%, net loss $10.1M (122.4% of revenue).
TriSalus Life Sciences, Q4 2024: revenue $8.3M (+44% year over year), operating margin -91.8%, net loss $10.1M, operating cash flow −$5.7M. The chart follows the revenue to costs, profit and cash.
| Q4 2024 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $8.3M | +12% | +44% |
| Operating profit | −$7.6M | — | — |
| Net earnings | −$10.1M | — | — |
| Operating cash flow | −$5.7M | — | — |
What changed
Revenue was $8.3M in Q4 2024, up 44% year over year and up 12% from the previous quarter.
Gross margin was 85.3%, down 4.5 points from a year earlier. Operating costs exceeded revenue by $7.6M, an operating margin of -91.8%. Operating expenses fell 25% while revenue rose 44%. The fastest-growing cost line was Sales & marketing (+25%). The quarter ended with a net loss of $10.1M, wider than the previous quarter's $2.4M loss.
Operating cash flow was −$5.7M. Non-cash charges added back $193K of depreciation and amortization and $1.7M of share-based compensation. Working capital and other items added $2.5M. Capital expenditures of $50K exceeded it, leaving free cash flow of −$5.8M.
Questions
What was TriSalus Life Sciences' revenue in the fourth quarter 2024?
TriSalus Life Sciences (TLSI) reported revenue of $8.3M for the fourth quarter 2024 (Q4 2024), +44% from a year earlier and +12% from the quarter before.
Was TriSalus Life Sciences profitable in the fourth quarter 2024?
Operating loss was $7.6M (-91.8% of revenue) and net loss $10.1M.